PREVENT equations are validated for ages 30β79. For ages 18β29, use 30-year risk estimate.Section 2.1.1, Table 2β
PREVENT uses sex-specific coefficients. Sex assigned at birth is used (not gender identity) for risk equations.Section 2.1.1, PREVENT derivation cohortβ
South Asian ancestry is a risk enhancer that may shift risk category upward (1.5β2Γ ASCVD risk at same risk factor levels).Section 4.2, Table 3 β Risk Enhancersβ
Statins and most nonstatins are contraindicated during pregnancy and lactation. Discontinue before planned conception.Section 4.2.8.1 β Pregnancy & Lactationβ
2
Medical History
π«
Cardiovascular & Metabolic Conditions
βΌ
ASCVD includes MI, stroke, PAD, coronary revascularization, etc. Very high-risk: recurrent ASCVD events, or ASCVD + multiple high-risk conditions. Post-ACS β€12 months is highest risk.Section 2.2 β Definitions; Section 4.2.5 β Secondary Preventionβ
Diabetes is a major ASCVD risk equivalent. For age 40β75 with LDL-C β₯70, start moderate- or high-intensity statin regardless of baseline LDL-C. Duration β₯20 years is a risk enhancer.Section 4.2.6 β Diabetesβ
Duration β₯20 years is a risk enhancer that may justify high-intensity statin over moderate-intensity in primary prevention.Section 4.2.6 β Risk Enhancers in Diabetesβ
CKD stage 3β4 is a risk enhancer. Treat with moderate-intensity statin + ezetimibe. Do NOT initiate statin in dialysis patients (unless already on statin).Section 4.2.8.4 β CKDβ
HIV is a risk enhancer. Moderate- or high-intensity statin recommended. Prefer pravastatin, rosuvastatin, pitavastatin (non-CYP3A4) to avoid ARV interactions.Section 4.2.8.6 β HIVβ
β‘
Risk Enhancers ?
βΌ
Risk enhancers modify risk category upward and influence treatment intensity, especially in borderline and intermediate risk. They do NOT have COR/LOE themselves but inform shared decision-making.Section 4.2.2 β Risk Enhancers (Table 3)β
First-degree male <55 yr or female <65 yr at ASCVD onset. Modifies risk category upward.Table 3β
Menopause before age 40 is a risk enhancer.Table 3β
"In adults with elevated Lp(a), optimize LDL-C management to lower goals regardless of baseline LDL-C."Section 4.2.10 β Elevated Lp(a)β
"Lp(a) β₯250 nmol/L is associated with approximately 2-fold increased ASCVD risk."Section 4.2.10β
PAD is ASCVD-equivalent. Treat with high-intensity statin, goal LDL-C <70 mg/dL.Section 4.2.5β
South Asian ancestry carries ~1.5β2Γ ASCVD risk at the same traditional risk factor levels and is a recognized risk enhancer.Table 3; Section 4.2.2β
LDL-C β₯160 mg/dL despite 3β6 months of intensive lifestyle modification is a risk enhancer, especially in young adults.Table 3β
CAC β₯100 or β₯75th percentile for age/sex/race effectively reclassifies to high risk and warrants high-intensity statin.Section 4.2.2.4 β CACβ
3
Basic Labs
π§ͺ
Lipid Profile
βΌ
Primary treatment target. Measured directly or by Friedewald/Martin-Hopkins calculation. Non-fasting acceptable unless TG β₯400 or FH suspected.Section 3.3 β LDL-C Measurementβ
If on statin, estimate untreated LDL-C for initial risk classification. Untreated LDL-C β treated LDL-C Γ 2 for high-intensity or Γ 1.4 for moderate-intensity.Section 3.5 β Estimating baseline LDL-Cβ
4
Advanced Labs
π¬
Biomarkers
βΌ
ApoB may be preferred as the primary marker for screening, diagnosis, and management (COR IIa). Alternative target: ApoB <80 mg/dL (high risk) or <65 mg/dL (very high risk).Section 3.4 β ApoBβ
COR I: Measure Lp(a) at least once in all adults. β₯125 nmol/L (β50 mg/dL) is elevated. β₯250 nmol/L β 2-fold ASCVD risk. Do not repeat unless considering therapy.Section 3.6 β Lp(a) Measurementβ
Required for PREVENT equations. eGFR should be re-checked within 3 months of statin initiation. Values <60 indicate CKD β use CKD-EPI equation.Section 3.7 β CKM Healthβ
Used in PREVENT equations. SBP + antihypertensive therapy status are both required. Target BP <130/80 in most patients with dyslipidemia.Section 3.7.1β
BMI is a PREVENT equation variable. Waist circumference adds metabolic syndrome assessment. Lifestyle goal: BMI 18.5β24.9, weight loss 5β10% if overweight/obese.Section 4.1 β Lifestyleβ
Smoking is a major ASCVD risk factor. Assessed in PREVENT equations. Counseling and cessation resources should be offered (COR I).Section 4.1 β Smoking Cessationβ
Routine CK monitoring in asymptomatic patients is NOT recommended (COR III: No Benefit). SAMS workup: rule out other causes, trial off 2β4 wk, rechallenge, switch to hydrophilic statin, then nonstatin if needed.Section 4.2.11 β SAMSβ
β οΈ SAMS Protocol
6
PREVENT Risk
π
AHA PREVENTβ’ Risk Score ?
βΌ
PREVENT equations replace PCE/ACC/AHA Pooled Cohort Equations. Race-free, CKM-integrated. Validated in US adults aged 30β79. Uses age, sex, TC, HDL-C, SBP, BP treatment, diabetes, smoking, eGFR, BMI.Section 2.1.1; Khan SS et al. Circulation 2024;149:1606β1635β
π Calculate PREVENT Risk
7
Decision Outputs
π―
Risk Category & LDL-C Goals
βΌ
π«
CAC Scoring
βΌ
π₯
Lifestyle Plan
βΌ
π
Pharmacotherapy
βΌ
π₯
Special Populations
βΌ
π
Triglyceride Check
βΌ
β οΈ
Drug Interactions
βΌ
π
Monitoring
βΌ
π
Clinical Summary
βΌ
π Generate Summary
2026 ACC/AHA Guideline on Management of Dyslipidemia Β· For clinical decision support Β· Individualize care